Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.98%19.74B | 6.81%5.08B | 3.00%5.04B | -0.74%4.85B | -1.08%4.76B | -0.39%19.35B | -1.67%4.76B | 0.82%4.9B | -0.41%4.89B | -0.29%4.81B |
Operating revenue | 1.98%19.74B | 6.81%5.08B | 3.00%5.04B | -0.74%4.85B | -1.08%4.76B | -0.39%19.35B | -1.67%4.76B | 0.82%4.9B | -0.41%4.89B | -0.29%4.81B |
Cost of revenue | 2.32%12.96B | 7.01%3.3B | 3.18%3.31B | -0.84%3.2B | 0.10%3.15B | 1.74%12.66B | -2.25%3.08B | 4.19%3.21B | 3.59%3.23B | 1.49%3.14B |
Gross profit | 1.33%6.78B | 6.44%1.79B | 2.67%1.73B | -0.54%1.65B | -3.30%1.61B | -4.17%6.69B | -0.59%1.68B | -5.01%1.69B | -7.39%1.66B | -3.47%1.67B |
Operating expense | -0.50%3.75B | 7.89%985M | 3.44%962M | -5.41%909M | -7.34%896M | -6.01%3.77B | -8.79%913M | -5.01%930M | -6.43%961M | -3.78%967M |
Selling and administrative expenses | -0.89%3.22B | 7.38%844M | 4.00%833M | -5.90%781M | -8.38%765M | -5.55%3.25B | -8.60%786M | -4.42%801M | -6.00%830M | -3.13%835M |
Depreciation amortization depletion | 1.93%529M | 11.02%141M | 0.00%129M | -2.29%128M | -0.76%131M | -8.79%519M | -9.93%127M | -8.51%129M | -9.03%131M | -7.69%132M |
-Depreciation and amortization | 1.93%529M | 11.02%141M | 0.00%129M | -2.29%128M | -0.76%131M | -8.79%519M | -9.93%127M | -8.51%129M | -9.03%131M | -7.69%132M |
Operating profit | 3.70%3.03B | 4.71%800M | 1.72%771M | 6.20%737M | 2.28%718M | -1.68%2.92B | 11.37%764M | -5.01%758M | -8.68%694M | -3.04%702M |
Net non-operating interest income expense | -23.53%65M | -60.87%9M | -19.05%17M | 0.00%20M | -9.52%19M | 112.50%85M | 21.05%23M | 90.91%21M | 233.33%20M | 425.00%21M |
Non-operating interest income | -5.56%119M | -17.65%28M | -3.13%31M | 0.00%30M | 0.00%30M | 113.56%126M | 25.93%34M | 88.24%32M | 233.33%30M | 400.00%30M |
Non-operating interest expense | 31.71%54M | 72.73%19M | 27.27%14M | 0.00%10M | 22.22%11M | 115.79%41M | 37.50%11M | 83.33%11M | 233.33%10M | 350.00%9M |
Other net income (expense) | 29.17%-153M | -81.58%-69M | 39.39%-40M | 77.17%-29M | -200.00%-15M | -2,800.00%-216M | -522.22%-38M | -2,300.00%-66M | -2,440.00%-127M | 1,400.00%15M |
Gain on sale of security | -1,050.00%-19M | -1,700.00%-18M | ---8M | 111.11%1M | -50.00%6M | -71.43%2M | -112.50%-1M | ---- | -125.00%-9M | --12M |
Special income (charges) | 41.48%-134M | -22.50%-49M | 54.17%-33M | 75.21%-29M | ---23M | ---229M | ---40M | ---72M | ---117M | --0 |
-Less:Restructuring and merger&acquisition | -29.30%111M | 181.25%26M | -54.17%33M | -75.21%29M | --23M | --157M | ---32M | --72M | --117M | --0 |
-Less:Impairment of capital assets | ---- | ---- | ---- | ---- | ---- | --1M | ---- | ---- | ---- | ---- |
-Less:Other special charges | -67.61%23M | ---- | ---- | ---- | ---- | --71M | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | ---- | ---- | -83.33%1M | 0.00%-1M | -33.33%2M | 1,000.00%11M | --3M | --6M | 0.00%-1M | 200.00%3M |
Income before tax | 5.42%2.94B | -1.20%740M | 4.91%748M | 24.02%728M | -2.17%722M | -7.59%2.79B | 4.90%749M | -12.19%713M | -22.86%587M | 1.23%738M |
Income tax | 6.74%713M | 2.05%199M | -10.99%170M | 33.06%165M | 13.29%179M | -8.49%668M | 1.04%195M | 4.37%191M | -32.61%124M | -7.06%158M |
Earnings from equity interest net of tax | 114.29%15M | 25.00%5M | 33.33%4M | --3M | --3M | 75.00%7M | --4M | --3M | --0 | --0 |
Net income | 5.36%2.24B | -2.15%546M | 10.86%582M | 22.25%566M | -5.86%546M | -7.16%2.13B | 7.10%558M | -16.53%525M | -19.76%463M | 3.02%580M |
Net income continuous Operations | 5.36%2.24B | -2.15%546M | 10.86%582M | 22.25%566M | -5.86%546M | -7.16%2.13B | 7.10%558M | -16.53%525M | -19.76%463M | 3.02%580M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 5.36%2.24B | -2.15%546M | 10.86%582M | 22.25%566M | -5.86%546M | -7.16%2.13B | 7.10%558M | -16.53%525M | -19.76%463M | 3.02%580M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 5.36%2.24B | -2.15%546M | 10.86%582M | 22.25%566M | -5.86%546M | -7.16%2.13B | 7.10%558M | -16.53%525M | -19.76%463M | 3.02%580M |
Basic earnings per share | 7.36%4.52 | -1.79%1.1 | 12.50%1.17 | 23.91%1.14 | -3.51%1.1 | -4.75%4.21 | 9.80%1.12 | -14.75%1.04 | -17.12%0.92 | 6.54%1.14 |
Diluted earnings per share | 7.13%4.51 | -0.90%1.1 | 12.50%1.17 | 25.27%1.14 | -3.51%1.1 | -4.54%4.21 | 8.82%1.11 | -14.75%1.04 | -18.02%0.91 | 6.54%1.14 |
Dividend per share | 3.45%1.2 | 3.45%0.3 | 3.45%0.3 | 3.45%0.3 | 3.45%0.3 | 7.41%1.16 | 7.41%0.29 | 7.41%0.29 | 7.41%0.29 | 7.41%0.29 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |